journal
MENU ▼
Read by QxMD icon Read
search

Antiviral Therapy

journal
https://www.readbyqxmd.com/read/27834772/early-neuropsychological-adverse-events-after-switching-from-pi-r-to-dolutegravir-could-be-related-to-hyperthyroidism-in-patients-under-levothyroxine
#1
Jean-Luc Berger, Yohan Nguyen, Delphine Lebrun, Caroline Migault, Maxime Hentzien, Hélène Marty, Firouzé Bani-Sadr
No abstract text is available yet for this article.
December 11, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27925609/a-comparison-of-virological-suppression-and-rebound-between-indigenous-and-non-indigenous-persons-initiating-combination-antiretroviral-therapy-in-a-multisite-cohort-of-individuals-living-with-hiv-in-canada
#2
Anita C Benoit, Jaime Younger, Kerrigan Beaver, Randy Jackson, Mona Loutfy, Renée Masching, Tony Nobis, Earl Nowgesic, Doe O'Brien-Teengs, Wanda Whitebird, Art Zoccole, Mark Hull, Denise Jaworsky, Anita Rachlis, Sean Rourke, Ann N Burchell, Curtis Cooper, Robert Hogg, Marina B Klein, Nima Machouf, Julio Montaner, Chris Tsoukas, Janet Raboud, Building Bridges
BACKGROUND: This study compared time to virologic suppression and rebound between Indigenous and non-Indigenous individuals living with HIV in Canada initiating combination antiretroviral therapy (cART). METHODS: Data were from the Canadian Observational Cohort collaboration; 8 studies of treatment-naïve persons with HIV initiating cART after 1/1/2000. Fine and Gray models were used to estimate the effect of ethnicity on 1) time to virologic suppression (two consecutive viral loads (VLs) <50 copies/mL at least three months apart) after adjusting for the competing risk of death and 2) time until virologic rebound (two consecutive VLs >200 copies/mL at least three months apart) following suppression...
December 7, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27924780/activity-of-ergoferon-against-lethal-influenza-a-h3n2-virus-infection-in-mice
#3
Maria A Skarnovich, Alexandra G Emelyanova, Nataliia V Petrova, Alena A Borshcheva, Evgeniy A Gorbunov, Oleg Yu Mazurkov, Maksim O Skarnovich, Sergey A Tarasov, Larisa N Shishkina, Oleg I Epstein
BACKGROUND: The Influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasising the further need for new effective treatments. One of them is Ergoferon, a drug, containing combined polyclonal antibodies - anti-interferon gamma, anti-CD4 receptor, and anti-histamine - in released-active form...
December 7, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27924779/hepatic-safety-of-maraviroc-in-patients-with-hiv-1-and-hepatitis-c-and-or-b-virus-144-week-results-from-a-randomized-placebo-controlled-trial
#4
Juergen K Rockstroh, Frank Plonski, Meena Bansal, Gerd Fätkenheuer, Catherine B Small, David M Asmuth, Gilles Pialoux, Rebecca Zhang-Roper, Ronnie Wang, Juan A Pineda, Jayvant Heera
BACKGROUND: In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), maraviroc-containing treatment regimens were not associated with increased hepatotoxicity. METHODS: In this randomised, double-blind, placebo-controlled, multicentre study, patients received maraviroc twice daily (n=70) or placebo (n=67) with concomitant antiretroviral therapy for 144 weeks (clinicaltrials...
December 7, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27922453/safety-and-efficacy-of-the-hiv-1-attachment-inhibitor-prodrug-fostemsavir-in-antiretroviral-experienced-subjects-week-48-analysis-of-ai438011-a-phase-iib-randomized-controlled-trial
#5
Melanie Thompson, Jacob P Lalezari, Richard Kaplan, Yvett Pinedo, Otto A Sussmann Pena, Pedro Cahn, David A Stock, Samit R Joshi, George J Hanna, Max Lataillade
BACKGROUND: Fostemsavir is a prodrug of temsavir, an attachment inhibitor that binds directly to HIV-1 gp120, blocking initial viral attachment and entry into host CD4 cells. Efficacy, safety, and dose-response data of fostemsavir in treatment-experienced, HIV-1-infected subjects, through Week 48, are reported. METHODS: AI438011 is an ongoing Phase IIb, randomized, active-controlled trial (NCT01384734). Subjects were randomized 1:1:1:1:1 into five arms: fostemsavir (400 mg twice daily [BID], 800 mg BID, 600 mg once daily [QD], or 1200 mg QD), and a reference arm (ritonavir-boosted atazanavir [ATV/r] 300/100 mg QD), each with a backbone of raltegravir 400 mg BID + tenofovir disoproxil fumarate 300 mg QD...
December 6, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27879484/herpes-simplex-type-2-encephalitis-and-methotrexate-medication-a-fortuitous-or-causative-association-in-a-patient-with-spondyloarthritis
#6
Julien Lupo, Ophélie Dos Santos, Raphaele Germi, Monique Baccard-Longère, Jean-Paul Stahl, Olivier Epaulard, Patrice Morand
It is unclear whether immunosuppression is a risk factor for herpes encephalitis. Herein, we describe a rare case of herpes simplex virus (HSV) type 2 encephalitis in a patient treated with low-dose methotrexate for HLA-B27-associated spondyloarthritis. The patient was successfully treated with acyclovir but presented sequelae of encephalitis. Here we discuss the possible role of low-dose MTX therapy as a risk factor of neurological herpes reactivation and severe disease. The host-related and viral risk factors are also addressed...
November 23, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27845298/daclatasvir-plus-sofosbuvir-with-or-without-ribavirin-in-real-world-patients-with-hiv-hcv-coinfection-and-advanced-liver-disease
#7
Jürgen K Rockstroh, Patrick Ingiliz, Jörg Petersen, Markus Peck-Radosavljevic, Tania M Welzel, Marc Van der Valk, Yue Zhao, Maria Jesus Jimenez Exposito, Stefan Zeuzem
BACKGROUND: HIV/HCV-coinfected patients respond just as well to modern direct-acting antiviral HCV therapy as HCV-monoinfected patients. However, clinical data for all-oral HCV treatments are sparse in HIV/HCV-coinfected patients with an advanced stage of liver cirrhosis. METHODS: A subanalysis of efficacy and safety for a daclatasvir (DCV) and sofosbuvir (SOF) regimen, with or without ribavirin (RBV), was undertaken in HIV/HCV-coinfected patients with advanced liver disease and no other treatment options enrolled into a European DCV compassionate use programme...
November 15, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27835613/efficacy-and-safety-of-tenofovir-containing-antiretroviral-therapy-in-women-who-acquired-hiv-while-enrolled-in-tenofovir-gel-prophylaxis-trials
#8
Nivashnee Naicker, Anushka Naidoo, Lise Werner, Nigel Garrett, Nelisile Majola, Villeshni Asari, Cheryl Baxter, Anneke Grobler, Quarraisha Abdool Karim, Salim S Abdool Karim
BACKGROUND: We assessed whether women who acquired HIV during tenofovir gel prophylaxis trials can be safely and effectively treated with tenofovir-containing antiretroviral therapy (ART). METHODS: Between May 2011 and October 2014, HIV seroconvertors from two tenofovir gel trials were recruited when eligible for ART (CD4 count <350 cells/μl, pregnancy or AIDS-defining illness). Women were randomised to tenofovir-containing (tenofovir + lamivudine/emtricitabine + efavirenz) or tenofovir-sparing (zidovudine + lamivudine/emtricitabine + efavirenz) antiretroviral treatment regimens...
November 4, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27805572/reporting-on-the-prevalence-of-antiretroviral-drug-resistance-in-a-regional-hiv-population-over-20-years-a-word-of-caution
#9
Victoria C Gill, Tarah Lynch, Soheil Ramazani, Hartmut B Krentz
BACKGROUND: Failure to achieve complete viral suppression with antiretroviral drugs (ARV) may lead to uncontrolled HIV replication, ARV resistance, and negative outcomes. Monitoring and reporting of HIV resistance trends is important but problematic. We examined prevalent resistance rates in a HIV population over 20 years and document how rates may appear to vary dramatically based solely on which parameters are utilized. METHODS: We determined the annual use of GART (genotypic antiretroviral resistance testing) from 1995 to 2014 for all patients receiving HIV care in southern Alberta, Canada, and the presence of resistance mutations in those tested...
November 2, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27805571/pharmacokinetics-and-safety-of-intravenous-peramivir-neuraminidase-inhibitor-of-influenza-virus-in-healthy-japanese-subjects
#10
Yutaka Saisho, Toru Ishibashi, Hidenori Fukuyama, Hiroyuki Fukase, Jingoro Shimada
BACKGROUND: Intravenous peramivir is a potent neuraminidase (NA) inhibitor with activity against influenza A and B viruses. The early use of NA inhibitors has been shown to reduce mortality in influenza patients. METHODS: To evaluate the pharmacokinetics of peramivir and confirm the safety and tolerability of multiple infusions of peramivir in healthy Japanese subjects, two Phase 1, single-center, randomized, double-blind, and placebo-controlled studies consisting of a multiple-dose study and a high-dose study were conducted...
November 2, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27786155/impact-of-tenofovir-disoproxil-fumarate-on-bone-metabolism-and-bone-mass-among-perinatally-hiv-infected-asian-adolescents
#11
Tavitiya Sudjaritruk, Torsak Bunupuradah, Linda Aurpibul, Pope Kosalaraksa, Nia Kurniati, Jiratchaya Sophonphan, Jintanat Ananworanich, Thanyawee Puthanakit
BACKGROUND: This study aimed to determine the effect of tenofovir disoproxil fumarate (TDF) on bone metabolism and bone mass in HIV-infected adolescents. METHODS: This was a sub-study of a cross-sectional multicenter bone health trial that enrolled perinatally HIV-infected Thai and Indonesian adolescents (10-18 years) with viral suppression on antiretroviral therapy. Participants were classified into 2 groups as TDF users and non-users. Bone metabolism-related markers [25-hydroxyvitamin D (25-OHD), intact parathyroid hormone (iPTH), bone turnover biomarkers], and lumbar spine dual-energy X-ray absorptiometry were assessed...
October 27, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27740538/economic-outcomes-of-influenza-in-hospitalized-elderly-with-and-without-icu-admission
#12
Yik-Kei Chan, Rity Yk Wong, Margaret Ip, Nelson Ls Lee, Joyce Hs You
BACKGROUND: To describe direct medical costs of influenza in hospitalized elderly, with and without intensive care unit (ICU) admission, during the 2014-2015 season in Hong Kong. METHODS: A retrospective study was conducted in 110 inpatients aged ≥65 years with laboratory-confirmed influenza treated by antiviral therapy during season 2014-2015 in a tertiary hospital. Resource utilization of influenza-related diagnostic and laboratory tests, medications for influenza treatment, usage of general medical ward and ICU during the influenza-related length of hospital stay (IR-LOS) were collected...
October 14, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27740537/hyperlipidaemia-in-hiv-infected-patients-on-lopinavir-ritonavir-monotherapy-in-resource-limited-settings
#13
Mitch M Matoga, Mina C Hosseinipour, Evgenia Aga, Heather J Ribaudo, Nagalingeswaran Kumarasamy, John Bartlett, Michael D Hughes
BACKGROUND: Cardiovascular disease (CVD) is an emerging concern for HIV-infected patients. Hyperlipidemia is a risk factor for CVD and a complication of protease-inhibitor-based antiretroviral therapy, but little is known about its incidence and risk factors in treated patients in resource-limited settings (RLS). METHODS: We conducted a secondary analysis of ACTG A5230 trial in which HIV-infected adults from India, Malawi, Tanzania, Thailand and South Africa, with virologic relapse on first line therapy were initiated on lopinavir/ritonavir (LPV/r) monotherapy...
October 14, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27740536/treatment-of-hiv-infection-with-a-raltegravir-based-regimen-increases-ldl-levels-but-improves-hdl-cholesterol-efflux-capacity
#14
Nicholas T Funderburg, Dihua Xu, Martin P Playford, Aditya A Joshi, Adriana Andrade, Daniel R Kuritzkes, Michael M Lederman, Nehal N Mehta
BACKGROUND: Persons infected with HIV often have altered lipid profiles that may be affected by antiretroviral therapies (ART). Traditional lipid measurements may be insufficient to assess cardiovascular disease (CVD) risk in this population. METHODS: We report results from 39 ART-naïve participants in a substudy of A5248, a single-arm study of raltegravir (RAL), emtricitabine/tenofovir administration. Samples were collected at baseline, 12, 24, and 48 weeks after ART initiation...
October 14, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27725337/maraviroc-ameliorates-the-increased-adipose-tissue-macrophage-recruitment-induced-by-a-high-fat-diet-in-a-mouse-model-of-obesity
#15
Patricia Pérez-Matute, José G Pichel, María Iñiguez, Emma Recio-Fernández, Laura Pérez-Martínez, Raquel Torrens, José Ramón Blanco, José Antonio Oteo
BACKGROUND: Any strategy designed to decrease the macrophage content in adipose tissue (AT) is of great value as a way to decrease inflammation in this fat depot and also as a way to prevent or treat obesity and associated disorders. Maraviroc (MVC), a CCR5 antagonist approved for the treatment of HIV-infected patients, has beneficial effects on metabolism. The objective of this study was to investigate the effects of MVC on AT macrophage recruitment in a mouse model of obesity. The plausible underlying mechanisms of action were also investigated...
October 11, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27708251/an-open-label-randomized-study-of-the-impact-on-insulin-sensitivity-lipid-profile-and-vascular-inflammation-by-treatment-with-lopinavir-ritonavir-or-raltegravir-in-hiv-negative-male-volunteers
#16
Paul Randell, Akil Jackson, Ana Milinkovic, Marta Boffito, Graeme Moyle
BACKGROUND: We aimed to measure the effect of raltegravir (RAL) on insulin sensitivity and surrogates of CV risk in healthy HIV-seronegative volunteers compared to that of lopinavir/r (LPV/r), a positive control. METHODS: An open label, two phase crossover study in HIV-negative male subjects randomized 1:1 to receive either 2 weeks of LPV/r followed by a two week washout period and two weeks of RAL, or RAL initially followed by LPV/r. A hyperinsulinaemic euglycaemic clamp was performed prior to and following each 2-week dosing phase...
October 6, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27705950/evolution-of-renal-function-in-african-patients-initiating-second-line-antiretroviral-treatment-findings-from-the-2lady-anrs-12169-trial
#17
Amandine Cournil, Arsène Hema, Sabrina Eymard-Duvernay, Laura Ciaffi, Stéphanie Badiou, Firmin N Kabore, Assane Diouf, Liliane Ayangma, Vincent Le Moing, Jacques Reynes, Sinata Koulla-Shiro, Eric Delaporte
BACKGROUND: To investigate change in renal function in African patients initiating second line ART including ritonavir-boosted protease inhibitor (PI/r) with or without tenofovir disoproxil fumarate (TDF). METHODS: HIV-1 positive adults, failing standard first line ART were randomized to either TDF/FTC+LPV/r; ABC+ddI+LPV/r or TDF/FTC+DRV/r and followed until 18 months. Patients with an estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1,73m(2) at baseline were included in this analysis...
October 5, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27694694/pharmacokinetics-of-intravenous-peramivir-in-the-airway-epithelial-lining-fluid-of-healthy-volunteers
#18
Yohei Funatsu, Sadatomo Tasaka, Takahiro Asami, Ho Namkoong, Hiroshi Fujiwara, Osamu Iketani, Kazuma Yagi, Yoshifumi Kimizuka, Makoto Ishii, Tomoyasu Nishimura, Haruhiko Ogata, Satoshi Iwata, Tomoko Betsuyaku, Naoki Hasegawa
BACKGROUND: Some subtypes of influenza virus, such as H5N1 and H7N9, cause severe viral pneumonia, for which the intraluminal concentration of the anti-influenza agent in the airway is critical. However, the pharmacokinetics of peramivir, the only available injectable neuraminidase inhibitor formulation, in the airway epithelial lining fluid (ELF) remains unclear. In this study, we aimed to determine the time course of peramivir in the pharyngeal ELF, bronchial ELF and plasma of healthy volunteers using bronchoscopic microsampling technique...
October 3, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27685337/effect-of-antiviral-therapy-for-hcv-on-lipid-levels
#19
Stefan Mauss, Florian Berger, Malte H Wehmeyer, Patrick Ingiliz, Dietrich Hueppe, Thomas Lutz, Karl G Simon, Knud Schewe, Juergen K Rockstroh, Axel Baumgarten, Stefan Christensen
HCV has complex interactions with human lipid metabolism leading to down regulation of cholesterol levels. Interferon therapy has been shown to decrease cholesterol even further. With the availability of second generation direct acting antiviral agents (DAA) the effect of suppressing and eliminating HCV on lipid metabolism warrants reevaluation. 
Methods: Prospective German multicenter cohort on HCV- and HIV/HCV-infected patients treated with direct antiviral agents (GECCO). Lipids were assessed at baseline, during and after therapy...
September 29, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27661787/salvage-therapy-or-simplification-of-salvage-regimens-with-dolutegravir-plus-ritonavir-boosted-darunavir-dual-therapy-in-highly-cart-experienced-subjects-an-italian-cohort
#20
Amedeo F Capetti, Giancarlo Orofino, Gaetana Sterrantino, Maria V Cossu, Giovanni Cenderello, Anna M Cattelan, Giuseppe V De Socio, Stefano Rusconi, Niccolò Riccardi, Gian M Baldin, Serena Cima, Fosca P Niero, Giuliano Rizzardini, Lolita Sasset
BACKGROUND: Dolutegravir plus darunavir provide high genetic barrier to HIV-1 resistance and fit for simple salvage regimens. METHODS: All HIV-1 infected subjects treated with dolutegravir plus boosted darunavir dual therapy between March 2011 and September 2015 were included in an observational cohort. Data were collected at baseline and at weeks 4, 12, 24 and 48. RESULTS: We enrolled 113 subjects. After week 24 one was lost at follow-up, one dropped out for grade 2 elevation of liver enzimes, one died from illicit drug abuse and one from cancer-related sepsis...
September 23, 2016: Antiviral Therapy
journal
journal
20043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"